MYBPC3 and cardiac hypertrophy: A single systemic administration of AAV9-MYBPC3 in 1-day-old KI mice prevented the development of cardiac hypertrophy and dysfunction during the observation period of 34 weeks and increased MYBPC3 messenger RNA (mRNA) and MYBPC3 protein levels in a dose-dependent manner [84].